The short version of glucagon receptor fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-02-19. Anything still debated is marked as such rather than presented as settled.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
== Vorkommen und Darstellung == Ethyl-2-cyano-2-(hydroxyimino)acetat wird bei der Reaktion von Cyanessigsäureethylester und Salpetriger Säure (aus Natriumnitrit und Essigsäure) in 87%iger Ausbeute erhalten.
Wegen der Hydrolyseneigung des Esters sollte die Reaktion bei pH 4,5 durchgeführt werden, wobei das Produkt in gepufferter Phosphorsäure in praktisch quantitativer Ausbeute anfällt. Die Verbindung kann durch Umkristallisieren aus Ethanol oder Ethylacetat gereinigt werden. Im Vergleich zu den als Peptidverknüpfungsreagentien weit verbreiteten und als explosionsgefährlich geltenden Benzotriazol-Derivaten 1-Hydroxybenzotriazol (HOBt) und 1-Hydroxy-7-azabenzotriazol (HOAt) zeigt Hydroxyiminocyanessigsäure-ethylester eine wesentlich verlangsamte thermische Zersetzung beim Erhitzen.
== Eigenschaften == Ethyl-2-cyano-2-(hydroxyimino)acetat ist ein weißer Feststoff, der in vielen, bei der Synthese von Peptiden üblichen, Lösungsmitteln, wie z. B. Dichlormethan (DCM) oder Dimethylformamid (DMF), löslich ist. Die Verbindung zersetzt sich oberhalb des Schmelzpunktes bei 128 °C stark exotherm mit einer Zersetzungswärme von −979 J·g−1 bzw. −139,1 kJ·mol−1. Als kristalline Substanz liegt die Verbindung als Oxim vor, während sie in anionischer Form als Salz oder in stark basischer Lösung überwiegend als tautomeres Nitrosoisomer existiert. Es sind zwei polymorphe Formen bekannt. Das Polymorph I kristallisiert in einem orthorhombischen Kristallgitter mit der Raumgruppe Pnma (Raumgruppen-Nr. 62)Vorlage:Raumgruppe/62 mit den Gitterparametern a = 7,997 Å; b = 6,512 Å und c = 13,622 Å sowie vier Formeleinheiten pro Elementarzelle. Das Polymorph II kristallisiert in einem monoklinem Kristallgitter mit der Raumgruppe P21/c (Raumgruppen-Nr. 14)Vorlage:Raumgruppe/14 mit den Gitterparametern a = 6,336 Å; b = 13,549 Å, c = 7,938 Å und β = 94,42 ° sowie vier Formeleinheiten pro Elementarzelle.
Sources: de.wikipedia.org
== Anwendungen == Aufgrund der einfachen präparativen Zugänglichkeit, des unkritischen Verhaltens bei Temperaturen unterhalb 80 °C und insbesondere wegen der hohen Ausbeuten und der geringen Racemisierung der erhaltenen Peptide hat Hydroxyiminocyanessigsäureethylester inzwischen eine weitere Verbreitung als Additiv bei Peptidsynthesen gefunden. Hydroxyiminocyanessigsäureethylester kann als Kupplungsadditiv bei der konventionellen Peptidverknüpfung in Lösung wie bei der automatisierten Merrifield-Synthese an einem festen Trägerharz (engl. solid-phase peptide synthesis (SPPS)) zusammen mit Kopplungsreagenzien wie Carbodiimiden, z. B. Dicyclohexylcarbodiimid (DCC), Diisopropylcarbodiimid (DIC) oder auch dem wasserlöslichen 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimid-Hydrochlorid (EDCI), eingesetzt werden.
Sources: de.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.